UDCA Pharmacokinetics and Biomarkers in Overweight Subjects with Liver Problems

Phase 1, randomised, open-label trial of ursodeoxycholic acid in non-alcoholic fatty liver disease (NAFLD) and Overweight (3 arms), sponsored by Seoul National University Hospital. Primary endpoints: Area under the plasma concentration-time curve of ursodeoxycholic acid at Day 57 and Change from Baseline Low-density lipoprotein cholesterol at 8 weeks. Status: unknown.